Amgen 2007 Annual Report Download - page 22

transplantation; and reducing the recovery time of neutrophils and the duration of fever following induction or
consolidation chemotherapy treatment in adult patients with acute myeloid leukemia (“AML”).
Worldwide NEUPOGEN®sales for the years ended December 31, 2007, 2006 and 2005 were $1.3 billion,
$1.2 billion and $1.2 billion, respectively.
Enbrel®(etanercept)
ENBREL is our registered trademark for our TNF receptor fusion protein that inhibits the binding of TNF to
TNF receptors, which can result in a significant reduction in inflammatory activity. TNF is one of the chemical
messengers that help regulate the inflammatory process. When the body produces too much TNF, it overwhelms
the immune system’s ability to control inflammation of the joints or of psoriasis-affected skin areas. ENBREL is
similar to a protein that the body produces naturally, and like this protein, it binds and deactivates certain TNF
molecules before they can trigger inflammation.
We acquired the rights to ENBREL in July 2002 as part of our acquisition of Immunex Corporation
(“Immunex”).
We market ENBREL under a co-promotion agreement with Wyeth in the United States and Canada (see
“Joint Ventures and Business Relationships — Wyeth”). The rights to market ENBREL outside of the United
States and Canada are reserved to Wyeth. ENBREL was initially launched in November 1998 by Immunex for
the treatment of rheumatoid arthritis. In addition, ENBREL is now indicated for the treatment of adult patients
with the following conditions: moderately to severely active rheumatoid arthritis, chronic moderate to severe
plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy; active psoriatic arthri-
tis and active ankylosing spondylitis. ENBREL is also approved for the treatment of moderately to severely
active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one
or more disease-modifying medicines.
We are in discussions with the FDA with respect to the class of TNF inhibitor agents around several safety
issues which may result in additional patient safety information in the form of a boxed warning that will apply to
the ENBREL label as has been the case with other TNF inhibitor agents.
ENBREL sales for the years ended December 31, 2007, 2006 and 2005 were $3.2 billion, $2.9 billion and
$2.6 billion, respectively.
Other
Other marketed products are principally comprised of Sensipar®(cinacalcet HCl) and Vectibix™
(panitumumab).
Sensipar®(cinacalcet HCl)
Sensipar®(Mimpara®in Europe) is our registered trademark for our first small molecule medicine used in
treating CKD patients on dialysis who produce too much parathyroid hormone, a condition known as secondary
hyperparathyroidism. In 2004, Sensipar®/Mimpara®was approved in the United States, Canada and Europe for
the treatment of secondary hyperparathyroidism in CKD patients on dialysis and for the treatment of hyper-
calcemia in patients with parathyroid carcinoma. We market Sensipar®/Mimpara®primarily in the United States
and Europe.
Sensipar®sales for the years ended December 31, 2007, 2006 and 2005 were $463 million, $321 million
and $157 million, respectively.
Vectibix™ (panitumumab)
Vectibix™ is our trademark for our first entirely human monoclonal antibody for the treatment of patients
with EGFr expressing mCRC after disease progression on, or following fluoropyrimidine-, oxaliplatin- and
irinotecan- containing chemotherapy regimens. EGFr is a protein that plays an important role in cancer cell sig-
10